Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Bio and Jiangsu Nhwa Pharma Join China-US-Canada CNS Collaboration

publication date: Apr 8, 2019

Shanghai I-Mab Biopharma and Jiangsu Nhwa Pharma have joined with two western healthcare organizations to develop a novel nasal-delivered immuno-stimulatory therapy for neurological diseases. The collaboration includes the Ann Romney Center for Neurologic Diseases at Brigham and Women's Hospital and Biodextris, a Montreal biologics CDMO. The Brigham team will be responsible for preclinical development including biomarkers and early clinical studies. I-Mab and Nhwa will provide financial, technical, regulatory, and business support for R&D and commercial development. More details....

Stock Symbol: (SHZ: 002262)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.